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METHODOLOGY
Direct transfer of HRPII-magnetic bead 
complexes to malaria rapid diagnostic tests 
significantly improves test sensitivity
Keersten M. Ricks1†, Nicholas M. Adams2†, Thomas F. Scherr2, Frederick R. Haselton1,2 and David W. Wright1*
Abstract 
Background: The characteristic ease of use, rapid time to result, and low cost of malaria rapid diagnostic tests (RDTs) 
promote their widespread use at the point-of-care for malaria detection and surveillance. However, in many settings, 
the success of malaria elimination campaigns depends on point-of-care diagnostics with greater sensitivity than 
currently available RDTs. To address this need, a sample preparation method was developed to deliver more biomark-
ers onto a malaria RDT by concentrating the biomarker from blood sample volumes that are too large to be directly 
applied to a lateral flow strip.
Methods: In this design, Ni–NTA-functionalized magnetic beads captured the Plasmodium falciparum biomarker 
HRPII from a P. falciparum D6 culture spiked blood sample. This transfer of magnetic beads to the RDT was facilitated 
by an inexpensive 3D-printed apparatus that aligned the sample tube with the sample deposition pad and a magnet 
beneath the RDT. Biomarkers were released from the bead surface onto the lateral flow strip using imidazole-spiked 
running buffer. Kinetics of HRPII binding to the Ni–NTA beads as a function of blood sample volume were explored 
prior to determining the effect of the proposed method on the limit of detection of Paracheck RDTs.
Results: More than 80 % of HRPII biomarkers were extracted from blood sample volumes ranging from 25 to 250 µL. 
The time required to reach 80 % binding ranged from 5 to 60 min, depending on sample volume. Using 250 μL of 
blood and a 30-min biomarker binding time, the limit of detection of the Paracheck Pf RDT brand was improved by 
21-fold, resulting in a limit of detection below 1 parasite/μL.
Conclusions: This approach has the sensitivity and simplicity required to assist in malaria elimination campaigns in 
settings with limited access to clinical and laboratory resources.
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Background
Malaria is a treatable infectious disease caused by a para-
site of the genus Plasmodium. In 2014, 97 countries and 
territories were documented to have ongoing malaria 
transmission, and 3.3 million people are estimated to 
be at risk of infection. As the global health community 
presses toward malaria elimination, the need for more 
sensitive point-of-care diagnostic tests becomes essential. 
Malaria rapid diagnostic test (RDT) demand has grown 
significantly in recent years. These lateral flow-based 
tests, which operate much like a commercial pregnancy 
test, detect protein biomarkers of malarial infection in 
a blood sample. The estimated need for malaria RDTs, 
in Africa alone, is 1.6 billion between the years of 
2013–2016 [1]. Compared to other diagnostic strategies 
(i.e., microscopy, traditional immunoassays and PCR), 
RDTs are more easily deployed for point-of-care testing 
because they are cost effective (<$1.50 per test), easy to 
use, tolerant of a wide range of environmental conditions, 
and offer a rapid time-to-result [2]. While they have been 
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useful in malaria control campaigns, the majority of com-
mercially available RDTs lack the sensitivity required 
to detect asymptomatic or submicroscopic infections 
(<200  parasites/µL of blood), which is critical for mov-
ing from malaria control to elimination campaigns [3–5]. 
Although it is unclear what degree of improvement in 
sensitivity is required for RDTs to be useful in elimina-
tion campaigns, there seems to be consensus from many 
groups that the 0.1–2 parasites/µL blood detection limit 
of polymerase chain reaction (PCR) is sufficient [6–10]. 
Furthermore, diagnostic tools with detection limits of 
1 parasite/µL blood have been cited as effective for active 
case detection and population surveillance [11]. Based 
on these values, it was anticipated that if the sensitivity 
RDTs can be improved to detect ~1 parasite/µL of blood, 
the current RDT-based approach for case management 
at the point-of-care has the potential to be effective for 
malaria elimination.
A number of strategies have been reported for enhanc-
ing the sensitivity of commercial RDTs, many of which 
focus primarily on amplifying the signal at the test line 
[12–14]. Others have explored RDT enhancement 
approaches based on the hypothesis that if an increased 
number of biomarkers can be delivered to the test from 
larger sample volumes without altering the function of 
the test, an enhancement in diagnostic capability would 
be observed [15–18]. The development of a magnetic 
bead-based sample preparation method was recently 
reported to purify and concentrate malaria biomarkers 
from whole blood [19, 20]. It was demonstrated that the 
predominate biomarker of Plasmodium falciparum infec-
tion, histidine-rich protein II (HRPII) could be extracted 
from a 100-µL whole blood sample with high efficiency 
and specificity using Ni–NTA functionalized magnetic 
particles, purified through a series of preloaded process-
ing solutions in a length of tubing, and concentrated into 
a 10-µL volume of elution buffer for downstream detec-
tion. Following the processing steps, the elution buffer 
was pipetted onto an RDT [19]. While the efficacy of this 
method for purification of pfHRPII from whole blood was 
initially evaluated by traditional protein detection meth-
ods (e.g., gel chromatography and ELISA), a significant 
increase in commercial malaria RDT signal was observed 
when the concentrated product was pipetted onto the 
test. This approach resulted in a fourfold to 13-fold 
enhancement in the limit of detection compared to RDTs 
performed using 5-µL blood samples as suggested by the 
manufacturer [20]. This proof of concept successfully 
demonstrated enhancement of unmodified commercial 
malaria RDTs, but the multi-step design of the protein 
purification method and the need for a pipette-based 
transfer step was at odds with the characteristic simplic-
ity and field-deployable nature of RDTs.
To maintain this ease-of-use which defines malaria 
RDTs but to still achieve enhancement in diagnostic abil-
ity, a new design was developed to: (i) directly transfer 
the HRPII-bead complex to the RDT in a single process-
ing step; and, (ii) release the HRPII directly onto the RDT 
(Fig. 1). The major advantages of this approach are that 
it does not replace the well-accepted and familiar RDT, 
but improves it with the addition of a simple bead-based 
concentration approach and additional user steps. Key 
variables of this new approach were explored to under-
stand the effects of sample volume, imidazole concentra-
tion, and bead mixing time on RDT performance and to 
determine if the limit of detection required for elimina-
tion campaigns could be achieved.
Methods
Materials
Ni–NTA Magnetic Agarose Beads (cat # 36111) were 
purchased from Qiagen Inc. Pooled human whole blood 
collected in citrate phosphate dextrose (CPD) anticoagu-
lant (cat # HMWBCPD) was purchased from Biorecla-
mation LLC. D6 P. falciparum stock culture was prepared 
in the Wright laboratory (18,450 parasites/µL stock 
concentration). Paracheck Pf RDTs (cat # 30301025) 
were acquired from Orchid Biomedical Systems. Flat-
cap 500  µL PCR tubes (cat # AB-0350) were purchased 
from Fisher Scientific. mBEADS dispensing tubes were 
prepared by cutting the end off of 500 µL PCR tubes at 
~1.5  mm from the bottom of the tube (the end oppo-
site of the cap), leaving an ~2.5 mm diameter hole in the 
bottom at the tube. The mBEADS transfer device was 
Fig. 1 Schematic of the biomarker extraction and delivery system. (1) 
Add blood to sample tube containing magnetic beads and lysis rea-
gents. (2) Mix the sample using a handheld, battery-powered vortex 
for 5–30 min to bind biomarkers. (3) Insert an RDT into the 3D printed 
transfer device. (4) Transfer the sample to a cut-bottom dispensing 
tube. (5) Insert the dispensing tube into the transfer device and wait 
30 s for the beads to collect near the bottom before depressing fully 
to blot the beads onto the test. The RDT is then developed using 
imidazole-spiked development buffer to release the biomarkers from 
the beads
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printed on a ProJet HD 3000 Plus 3D printer (an image of 
the device is provided in Additional file 1: Figure S1). The 
Qiagen ESEQuant Lateral Flow Reader and software was 
acquired from Qiagen Lake Constance. All other materi-
als and reagents were purchased from Fisher Scientific.
Image analysis of blood clearance from the lateral flow 
strip
In order to examine the inherent purification capabili-
ties of the lateral flow strip, blood volumes of 0, 5, 10, 
15, 20, 25, 50, and 100 µL, each containing 200 parasites/
µL, were run on Paracheck RDTs according to the manu-
facturer’s recommended procedure. A Nikon D800 36.3 
MP D-SLR camera (Nikon Inc., Melville, NY, USA) with 
a AF-S Nikkor 24–85 mm f/3.5-4.5G ED VR lens (Nikon 
Inc., Melville, NY, USA) was positioned above the RDTs, 
and was sufficiently elevated to avoid shadowing the 
RDTs below. The camera was used in time-lapse mode to 
collect images every 4 s for 30 min. The resulting images 
were read into a custom image analysis program devel-
oped in MATLAB v8.5 (MathWorks, Natick, MA, USA). 
For each frame, two regions of interest were manually 
selected on the RDTs. Average pixel intensity inside a 
preselected region upstream of both the control and test 
lines on the membrane was measured as the test area, 
and average pixel intensity from a second region on the 
plastic cartridge of the RDT was use for white-balance 
correction. White balance normalization of the test area 




I¯W , where I˜T is the 
normalized pixel intensity of the test area, ĪW is the aver-
age pixel intensity of the white-balance area, and ĪT is the 
average pixel intensity of the test area.
Effect of sample volume on binding kinetics of HRPII to Ni–
NTA magnetic particles
Samples were prepared by spiking whole blood with D6 
P. falciparum parasite culture to a final concentration of 
200 parasites/µL, in order to closely mimic a patient sam-
ple. The blood was lysed at a 1:1 ratio with lysis buffer, 
and 50, 100, 200, or 500 µL volumes of lysed blood plus 
20  µL of Ni–NTA magnetic particles were added to 
1.5  mL Eppendorf tubes (n  =  3 for each time point). 
The manufacturer-estimated binding capacity of 20  µL 
of bead suspension (40 µg) was estimated to be in great 
excess of the amount of HRPII present. The tubes were 
placed on a bench top vortexer fitted with a tube holder 
attachment and vortexed for 5, 10, 15, 30, or 60  min at 
medium speed. For each time point, three tubes from 
each sample volume were spun down on a minicentrifuge 
for 10 s to collect the sample and beads at the bottom of 
the tube. The tubes were then placed on a magnetic tube 
rack to pull the magnetic particles to the side of the tube 
while the blood sample supernatant was collected. The 
blood supernatant samples for each sample volume at 
each time point were analyzed by ELISA for HRPII con-
tent, using a previously published method [19].
Using these binding kinetics data, and with the assump-
tion that mass transfer to the bead surface is rapid, the 
dissociation of bound biomarker is negligible, a constant 
volume is maintained, the system is well-mixed, and that 
the surface density of Ni–NTA is always in excess and its 
concentration remains in excess, a mole balance on free 
HRPII is solved to yield:
where NHRPII0     is the initial moles of biomarker, and K is 
a lumped constant proportional to the forward reaction 
rate constant, k, and the initial moles of Ni–NTA given 
by the product of the number of magnetic beads and the 
surface density of Ni–NTA. To determine the kinetic 
binding parameter, K, the fraction of HRPII remaining as 
a function of time and sample volume was fit using a non-
linear least squares method in the Curve Fitting Toolbox 
of MATLAB v8.5 (MathWorks, Natick, MA, USA).
Effect of sample volume on limit of detection of Paracheck 
RDT
Paracheck Pf RDTs were chosen for these studies because 
they have been identified by the WHO as a top perform-
ing test brand [21], they have been demonstrated to 
have relatively reliable quality standards and high sensi-
tivity [19], and they can be obtained for research use in 
the USA. The limit of detection of the magnetic bead-
enhanced Paracheck Pf RDTs was determined after con-
centrating biomarkers from blood sample volumes of 
25, 50, 100, or 250 µL lysed blood spiked with increasing 
parasite concentrations corresponding to the linear range 
of the RDT’s signal response curve from that volume (0, 
5, 10, 25, and 50 parasites/µL for the 50 µL sample vol-
ume series, 0, 1, 5, 10, and 25 parasites/µL for the 100 µL 
sample volume series, 0, 1, 5, 10, and 25 parasites/µL for 
the 200 µL sample volume series, and 0, 0.5, 1, 5, and 10 
parasites/µL for the 500 µL sample volume series). Each 
sample concentration was run in triplicate. The samples 
were lysed at a 1:1 ratio of whole blood to lysis solution 
and incubated with 20 µL of Ni–NTA magnetic beads for 
30 min on a benchtop vortexer. During mixing, the RDT 
was removed from the packaging and inserted into the 
transfer device. After mixing, the lysed blood and bead 
sample was transferred into the cut opening of a dispens-
ing tube using a plastic transfer pipette. The dispensing 
tube was inverted cut-side-down and placed in the sam-
ple port of the transfer device. With the cap closed, the 
surface tension of the meniscus at the bottom of the dis-
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the tube. The magnetic beads were collected at the bot-
tom of the tube by the magnet positioned below the 
RDT for 30  s, and then the dispensing tube was gently 
depressed ~2 mm to blot the beads on to the sample pad. 
The RDT was removed from the transfer device prior 
to adding to the buffer port 90 µL of the manufacturer-
provided running buffer spiked with 500 mM imidazole. 
The RDT developed for 30  min. The lateral flow strip 
was then removed from the cassette and the peak area 
of the test line was measured using a Qiagen ESEQuant 
LFR. The average signal from the triplicate runs for each 
parasite concentration was plotted, and the linear regres-
sion was calculated and normalized by subtracting the 
average signal of the 0 parasite/µL blank. The lower limit 
of detection was calculated using the linear regression 
(y =  ax +  b) for each sample volume tested by solving 
for the parasite concentration (x) at the limit of blank (y). 
The limit of blank was calculated as the mean of the blank 
measurements plus three times the standard deviation of 
the 0 parasite/µL measurements. The limit of detection of 
the Paracheck Pf RDTs performed using 5 µL blood sam-
ples without biomarker enhancement was determined 
using the same method.
Paracheck peak area analysis by Qiagen ESEQuant LFR
Using the LR Studio software supplied with the reader, a 
method was set up to read lateral flow strips from Para-
check RDTs. To do this, a Paracheck RDT was developed 
using a 2000 parasites/µL sample. After developing the 
test, the lateral flow strip was removed from the plastic 
housing, the wicking pad removed, and the strip was then 
placed in the LFR tray with the wicking end of the strip 
against the left edge of the tray. In the software, the chan-
nel and type was set to E1/D2 and reflective, respectively. 
The LFR was set to read from 0 to 60 mm, and the signal 
noise threshold was set to 1  mV. The software was also 
set to evaluate peak area at a fixed baseline, measuring 
left and right 1.5  mm. After entering these parameters, 
the green arrow was clicked to scan the strip. After the 
scan was complete, the vertical trace was placed over the 
center of the control line before double clicking on the 
‘Pos [mm] box’. This parameter was saved as the ‘Control’. 
After adding a new parameter (Test → Add New Param-
eter), this process was repeated to set up the ‘Test’ line 
reading. Both the Control and Test parameters were then 
saved as the Paracheck method file. This method file was 
used to analyse and calculated the peak areas for each of 
the processed Paracheck RDTs.
Results
Effect of increased blood sample volume on RDT clearance
In the case of biomarker-based malaria diagnostics, using 
larger patient blood sample volumes has the potential 
to improve the probability of detecting low abundance 
parasite biomarkers. Current RDTs rely on lancets to 
collect a small drop of blood (5–10  µL), however, with 
the increasing availability of simple blood collection 
techniques using ‘high-flow’ lancets, it has been dem-
onstrated that blood volumes of 250 µL or more can be 
reliably collected from finger pricks at the point-of-care 
[22, 23]. Because RDT signal intensity is directly related 
to the number of biomarkers that reach the test line, one 
approach to improving the sensitivity of RDTs might be 
to add a larger blood sample volume (and thus more bio-
markers) to the sample pad. If this approach enhanced 
RDT signal, adding a sample preparation step to concen-
trate the biomarkers would be of little value. The limits of 
this increased blood volume strategy was determined for 
the Paracheck Pf RDTs without modifying the volume of 
running buffer added to the test. RDT performance and 
lateral flow strip ‘clearing’ was evaluated over the 30-min 
time course recommended by the manufacturer. Clear-
ing refers to the lateral flow strip returning to the original 
white background colour after a blood sample has flowed 
down the lateral flow strip and been absorbed into the 
wicking pad. If blood does not clear from the test, the lat-
eral flow test generally does not develop properly, the test 
line often becomes masked by the blood, and antigen–
antibody interactions at the test and control line may be 
inhibited. Blood sample volumes of 0, 5, 10, 15, 20, and 
50  µL containing 200 parasites/µL were run on Para-
check Pf RDTs. After 30 min, the RDT with 5 µL blood 
completely cleared, with pixel intensity near the baseline 
value; the RDT with 10  µL blood partially cleared, with 
pixel intensity trending downward; and the RDTs with 
15  µL or more blood did not clear, with pixel intensity 
trending upward or remaining high (Fig. 2a). In the repre-
sentative images of the RDTs from the 30-min time point 
(Fig.  2b), it is demonstrated that the RDT performed 
with 5 µL blood developed properly, as no blood is vis-
ible on the sample pad or the area of the lateral flow strip 
around the test and control lines (left image). The RDT 
performed with the 10 µL sample is nearly cleared, as no 
blood is visible on the sample pad but has not cleared the 
test and control line area (second image from the left). 
In the RDTs performed with 15 and 20 µL, capillary flow 
was noticeably inhibited, as blood was left on the sam-
ple pad, the test lines were masked by the red colour of 
the blood, and the control lines did not develop properly 
(right two images). Time-lapse video of RDT clearance 
of each blood sample volume tested is available in the 
Additional file 2. These data demonstrate that delivering 
more HRPII to the lateral flow strip by simply increasing 
the sample volume applied to the test is not feasible using 
Paracheck Pf RDTs because of poor RDT clearance and 
performance when using blood volumes >10 µL.
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Effect of sample volume on bead‑binding kinetics
RDT signal enhancement would be expected to increase 
as biomarkers are concentrated from larger sample vol-
umes and delivered to the test line. However, during the 
magnetic bead capture step, if the number of magnetic 
beads remains constant, increasing the sample volume 
increases the diffusion distance that must be overcome 
for HRPII to bind the Ni–NTA on the surface of the 
magnetic beads, thus decreasing the probability of bind-
ing events for any given capture time. Therefore, it was 
predicted that for a fixed number of beads as sample vol-
ume increased, the time required to bind an equivalent 
portion of HRPII from the sample would also increase. 
To determine the effect of sample volume on biomarker 
binding kinetics, sample volumes of 25, 50, 100, and 
250  µL containing 200 parasites/µL were mixed with 
20 µL of beads for 5, 10, 15, 30, or 60 min, and the amount 
of HRPII remaining in the solution after the beads were 
removed was quantified by ELISA (Fig.  3). This volume 
of magnetic beads was selected based on previous work 
[19]. At 30  min, only 5  % of the initial HRPII remained 
in the 25-µL sample, whereas in the 250-µL sample, 30 % 
of the protein remained. Most of the protein was bound 
from the 25 and 50-µL samples after 1 h, where 10 and 
16  % remained in the 100 and 250-µL samples, respec-
tively. A fit of this collective sample volume and time 
data found the parameter K from Eq.  1 to be 21.53  μL/
min (95 % confidence bounds: 17.49, 25.57; R2 = 0.9247). 
These data support the conclusion that increasing sam-
ple volume while fixing the number of beads increases 
the time required to bind a particular portion of available 
HRPII to the Ni–NTA-functionalized the bead surface.
Effect of initial blood sample volume on limit of detection 
of Paracheck RDTs
To assess whether concentrating biomarkers from a 
larger sample volumes improves RDT performance, the 
limit of detection of this approach was determined by 
generating signal response curves over a range of parasite 
concentrations for each sample volume (see Additional 
file 1: Figure S2). Based on the analysis of these data, it 
was determined that the limit of detection improved 
when using magnetic beads to concentrate HRPII from 
Fig. 2 Image analysis of the clearance of blood from Paracheck Pf 
RDTs over a 30-min time course after adding 5, 10, 15, 20, or 50 µL of 
blood directly to the test. a Pixel intensity increases as blood flows 
onto the lateral flow strip and decreases as the blood is cleared from 
the strip by the running buffer. b Representative images of RDTs 
performed with 5, 10, 15, and 20 µL blood after 30 min. Proper RDT 
development is assessed by visualizing blood clearance from the 
sample pad and the area around the test and control lines. Time-
lapse video of RDT clearance is available as an additional file online
Fig. 3 Percentage of total HRPII remaining in the lysed blood sample 
after mixing with Ni–NTA-functionalized magnetic beads over the 
course of 60 min from blood sample volumes of 25, 50, 100, and 
250 µL containing 200 parasites/µL
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larger sample volumes (Table  1). An enhancement fac-
tor, defined as the ratio of the limit of detection using the 
magnetically enhanced approach to the limit of detection 
of unenhanced Paracheck, was also calculated for each 
sample volume. Using a sample volume of 250 µL and a 
30-min HRPII capture step, a 21-fold improvement over 
unenhanced Paracheck RDT performance was achieved, 
and more importantly, resulted in a limit of detection 
below 1 parasites/µL. At each sample volume tested, RDT 
signal enhancement was observed over an unenhanced 
RDT, yet less enhancement was observed at smaller sam-
ple volumes as fewer HRPII molecules were delivered 
to the lateral flow strip. Control RDTs were also run at 
each sample volume without parasites added to ensure 
that the method did not concentrate non-target proteins 
that could lead to false positives. For each control sam-
ple volume tested, the RDT reader did not read a value 
at the test line, as there was no signal at this region (see 
Additional file 1: Figure S3). While it is known that HRPII 
concentrations in vivo can be variable among different P. 
falciparum strains and is dependent on the developmen-
tal stage of the parasite, for these method development 
studies, dilution of stock D6 parasite culture provided a 
useful metric with minimal variability so that the focus 
of the studies were on device variability rather than sam-
ple-to-sample variability [24]. Additionally, a 200-fold 
dilution of 200 parasites/µL may not fully represent the 
complex physiological response of a malaria patient with 
a circulating infection of 1 parasite/µL, but representa-
tion of the enhancement method as such demonstrates 
how these RDTs can be utilized, as currently manufac-
tured, to achieve PCR-like limits of detection.
Benefits and trade‑offs of the magnetically enabled 
biomarker delivery approach
Because commercial RDTs are manufactured with 
buffer solutions, reagents and materials that are opti-
mized for intracompatibility and test performance, it 
is remarkable that the magnetically enabled biomarker 
delivery approach does not impede RDT function. The 
compatibility of the approach with commercial RDTs is 
the result of a few interesting phenomena. The first is that 
the fluid dynamics and imidazole concentration of the 
running buffer are sufficient to release the HRPII from 
the blotted bead mound within the time frame required 
for the HRPII to bind to the gold nanoparticle conjugates 
as they flow up to the RDT test lines. The second is that 
despite being deposited directly on top of the lateral flow 
strip, as shown in Fig.  4, the Qiagen Agarose Ni–NTA 
magnetic beads do not appear to disrupt the flow of sam-
ple and buffer as the test develops. Thirdly, the addition 
of imidazole does not significantly impact the antibody 
binding, signal generation, or the general performance 
of the RDT (see Additional file  1: Figure S4). Also, it 
was found that for blood sample volumes in the range of 
50–250 µL, the amount of blood component transferred 
to the test was <10 µL (see Additional file 1: Figure S5), 
which is within the allowable range of blood volumes 
determined in Fig. 2.
Despite the compatibility of this new approach with 
Paracheck Pf RDTs and the enhancement in RDT perfor-
mance when using these HRPII bound magnetic beads, 
there are areas in which the method could be further 
improved. Given the expected concentration factors from 
the larger sample volumes, the maximum theoretical 
enhancement factors are greater than the experimentally 
determined values. For example, the 250-µL blood sam-
ple produced a 21-fold enhancement in Paracheck’s limit 
of detection, but based on the volume ratio (250–5 µL), 
the enhancement potential is 50-fold. One factor that 
contributes to this disparity is the trade-off between 
the volume of the blood sample and the time it takes to 
bind a certain percentage of the biomarkers present. The 
Table 1 Limit of  detection and  enhancement factor 
of  magnetic bead-enhanced RDTs relative to  an unen-
hanced RDT
a Control RDT performed according to manufacturer’s protocol








Fig. 4 Paracheck RDTs before (top) and after (bottom) magnetic 
bead-based enhancement. The top RDT shows the result of applying 
a 5 µL blood sample containing 200 parasites/µL according to the 
manufacturer’s protocol. The bottom RDT shows enhancement at the 
test line after using the bead transfer device to apply HRPII-bound 
magnetic beads after mixing with a 100 µL sample containing 
200 parasites/µL. HRPII is released from the deposited beads with 
imidazole-spiked running buffer
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percentage of HRPII captured from the 250-µL blood 
sample after 30 min is 67 % (Fig. 3). For a fixed number 
of magnetic beads, the parameters under experimental 
control, namely time and volume, are inversely propor-
tional (refer to Eq. 1), therefore, to increase the amount 
of HRPII captured on the bead surface, larger sample 
volumes will require longer incubation times. However, 
increasing the other factors contained in K (i.e., the num-
ber of beads, surface density of Ni–NTA, and the binding 
kinetics of HRPII to the bead surface) will also improve 
the capture efficiency for any given time and volume.
Effective transfer of biomarker-bound magnetic beads 
to the RDT is key to the performance of the enhancement 
method. The ‘blotting’ approach that is currently used to 
transfer bead from the dispensing tube to the lateral flow 
strip effectively and reproducibly transfers beads to the 
RDT. However, the amount of blood that is transferred to 
the RDT during blotting varies between 5 and 10 µL (10 
and 20 µL of total lysed blood solution) depending on the 
user’s blotting technique (see Additional file 1: Figure S5). 
This variation in liquid transfer likely contributes to run-
to-run signal error. Additionally, the efficiency of HRPII 
elution from the pellet of blotted beads may account for 
some of the losses. Elution efficiency may be improved 
by maximizing the interactions of the bead surface with 
imidazole by distributing the beads more evenly on the 
lateral flow strip or adding imidazole directly to the blot-
ted beads. Future efforts will focus on minimizing the 
amount of residual sample transferred and maximizing 
bead surface interactions with imidazole.
Another important variable in some point-of-care set-
tings is cost per assay. Commercial malaria RDTs cost 
US$0.55–$1.50 per test [2]. The additional cost of mate-
rials in the proposed method is dominated by the cur-
rent low-volume cost of the Qiagen Ni–NTA magnetic 
beads (~US$2.20 per test). Based on the commercial 
availability of Ni–NTA bead options that are significantly 
less expensive than those used in this study, it is expect 
that the additional cost per assay can be reduced to 
much less than US$1.00. Despite this additional cost 
per assay, the limit of detection of the enhanced RDT 
method approaches that of current PCR-based strategies 
and, therefore, has the potential to significantly reduce 
the costs and infrastructure required for elimination 
campaigns.
Conclusions
A simple magnetic bead-based sample preparation 
approach was shown to enhance a commercial malaria 
RDT by up to 21-fold, resulting in a limit of detection 
less than 1 parasite/µL without physically altering the 
RDT. The approach concentrates HRPII biomarkers from 
whole blood sample volumes that exceed the volume 
capacity of the RDT by capturing the HRPII from the 
samples using Ni–NTA functionalized magnetic beads, 
magnetically transferring the beads in a small volume to 
the RDT, and releasing the HRPII onto the RDT using 
imidazole-spiked running buffer. This approach features 
a simple, robust and low-cost format usable in settings 
with limited access to trained medical personnel and 
laboratory resources. Future work aims to streamline the 
sample collection tube integration with blood collection 
from a finger prick and modify the 3D-printed housing 
for ease-of-use with other RDT brands. It is anticipate 
that the improved performance of RDTs, due to deliv-
ery of more biomarkers from asymptomatic carriers, 
will result in an immediate impact in malaria elimination 
campaigns by enabling identification of asymptomatic 
patients.
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